Meta-Analysis Comparing P2Y12 Inhibitors in Acute Coronary Syndrome
Luca Baldetti1, Francesco Melillo2, Francesco Moroni1
1Cardiac Intensive Care Unit, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy.
Insights
Prasugrel demonstrated superior efficacy over clopidogrel and ticagrelor in reducing major adverse cardiovascular events and stent thrombosis in acute coronary syndromes (ACS) patients. This network meta-analysis suggests prasugrel is the optimal P2Y12 inhibitor for reducing adverse outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is standard for acute coronary syndromes (ACS).
- The comparative effectiveness and safety of different P2Y12 inhibitors in ACS remain incompletely understood despite recent trials.
Purpose of the Study:
- To conduct a network meta-analysis comparing the efficacy and safety of various P2Y12 inhibitors in ACS patients.
- To identify the optimal P2Y12 inhibitor for reducing atherothrombotic events and improving outcomes in ACS.
Main Methods:
- Systematic review and network meta-analysis of 14 studies involving 145,019 patients, adhering to PRISMA guidelines.
- Frequentist network meta-analysis with surface under the cumulative ranking probability (SUCRA) analysis.
- Endpoints included major adverse cardiovascular events (MACE), all-cause death, myocardial infarction (MI), stent thrombosis (ST), and major bleeding at 30 days and 1 year.
Main Results:
- At 30 days, prasugrel was superior to clopidogrel and ticagrelor for MACE, all-cause death, and definite ST. Prasugrel and ticagrelor were superior to clopidogrel for MI.
- At 1 year, prasugrel and ticagrelor reduced all-cause death versus clopidogrel; prasugrel also reduced MI versus clopidogrel.
- No significant differences in 30-day major bleeding or 1-year MACE were observed among the agents. Prasugrel ranked highest for efficacy and safety across endpoints.
Conclusions:
- Prasugrel demonstrated the highest efficacy in reducing adverse cardiovascular events and hard adverse events in ACS patients at both 30-day and 1-year follow-up.
- Prasugrel showed the highest probability of being the best P2Y12 inhibitor for improving outcomes in ACS.
- The findings support prasugrel as a preferred P2Y12 inhibitor choice for ACS management.
Abstract:
Dual antiplatelet therapy combining aspirin with a P2Y12-receptor inhibitor reduces atherothrombotic events following an acute coronary syndromes (ACS), but the relative merits of different P2Y12 inhibitors remain unclear, despite several recent large-scale trials. We performed a network meta-analysis, representing the largest evidence to date to inform P2Y12 inhibitor choice in patients with ACS. Fourteen studies were included, for a total population of 145,019 patients. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were used in this systematic review. A network meta-analysis using a frequentist approach with surface under the cumulative ranking probability calculation was performed. Major adverse cardiovascular events (MACE), all-cause death, myocardial infarction (MI), definite stent thrombosis (ST) and major bleeding at 30-day and 1-year all-cause death and MI were the study endpoints. At 30-day, prasugrel was superior to both clopidogrel and ticagrelor in MACE, all-cause death and definite ST endpoints. Both prasugrel and ticagrelor were superior to clopidogrel in MI endpoint. Ticagrelor also reduced all-cause death compared with clopidogrel. Ticagrelor, prasugrel, and clopidogrel resulted equivalent in terms of the safety outcome of 30-day major bleeding. No significant difference was found among clopidogrel, prasugrel, and ticagrelor with respect to 1-year MACE outcome. Both prasugrel and ticagrelor reduced the occurrence of 1-year all-cause death compared with clopidogrel. Prasugrel reduced 1-year MI rate as compared with clopidogrel, while ticagrelor did not. At probability analyses, prasugrel ranked best in all 30-day and 1-year efficacy and safety endpoints. In conclusion, in this network meta-analysis, prasugrel showed the highest efficacy in reducing adverse outcomes in ACS patients and had the highest probability of being the best P2Y12 inhibitor to reduce hard adverse events both at 30-day and 1-year follow-up.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Coronary Syndrome I: Introduction
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Acute Coronary Syndrome V: Nursing Management